J Cancer 2018; 9(23):4355-4362. doi:10.7150/jca.26902
Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis
1. Department of Breast Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China;
2. Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;
3. School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China;
4. Department of Biochemistry and Molecular Medicine, The George Washington University Medical School, Washington, DC, USA.
*LH Z, C D and T T contributed equally to this work.
Zhou L, Dai C, Tian T, Wang M, Lin S, Deng Y, Xu P, Hao Q, Wu Y, Yang T, Zhu W, Dai Z. Prognostic Values of LAPTM4B-35 in Human Cancer: A Meta-analysis. J Cancer 2018; 9(23):4355-4362. doi:10.7150/jca.26902. Available from http://www.jcancer.org/v09p4355.htm
Background: Lysosome-associated protein transmembrane-4β-35(LAPTM4B-35) has been observed overexpressed in multiple malignant tumors. However, the prognostic value of LAPTM4B-35 remains controversial. Therefore, we conducted a meta-analysis to evaluate the prognostic value of LAPTM4B-35 in human cancers.
Methods: The relevant publications were obtained by systematically searching the PubMed, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI) databases. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for the prognosis value of LAPTM4B-35 for cancer patient.
Results: Our result suggest that LAPTM4B-35 overexpression is significantly associated with poor overall survival (OS) (HR = 2.49, 95% CI = 1.87-3.32, p < 0.001), disease-free survival (DFS) (HR = 2.43, 95% CI = 1.35-4.35, p = 0.003), and progression-free survival (PFS) (HR = 4.12, 95% CI = 2.30-7.37, p < 0.001). Moreover, subgroup analysis revealed significant association with poor OS in lung (HR = 2.05, 95% CI = 1.37-3.06, p < 0.001), gastric carcinoma (HR = 1.88, 95% CI = 1.01-3.50, p < 0.047) and ovarian cancer (HR = 4.94, 95% CI = 1.44-16.94, p = 0.011).
Conclusion: LAPTM4B-35 may be a novel predictive biomarker and a potential target for treatment.
Keywords: LAPTM4B-35, cancer, prognosis, meta-analysis